Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.08.024Source: DataRank Database

UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma is a research paper published in Journal of Thoracic Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 38 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access38 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.08)OA: bronzeTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Vivek Shukla,Sichuan Xi,Sudheer Kumar Gara,Yi Liu ORCID,David M. Straughan

Live enrichment

PubMed:32927122 PMC:PMC7775915 OpenAlex:https://openalex.org/W3086385173

National Institutes of Health

Grant: ZIA BC 011115

National Cancer Institute

Grant: 2 R01 CA120528-12

NCI NIH HHS

Grant: R01 CA120528

NCI NIH HHS

Grant: P30 CA016042

National Cancer Institute

National Institutes of Health

FWCI

2.08

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.jto.org/article/S1556086420307164/pdf

publisherhttp://www.jto.org/article/S1556086420307164/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1556086420307164?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1556086420307164?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtho.2020.08.024

Fields of Study

Occupational and environmental lung diseasesEpigenetics and DNA MethylationCystic Fibrosis Research AdvancesAnimalsCCAAT-Enhancer-Binding ProteinsCell Line, TumorCell ProliferationEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantMicePleural NeoplasmsUbiquitin-Protein Ligases

MeSH Terms

Mesothelioma, MalignantAnimalsHumansLung NeoplasmsMesotheliomaPleural NeoplasmsGene Expression Regulation, NeoplasticCCAAT-Enhancer-Binding ProteinsEpigenesis, GeneticUbiquitin-Protein LigasesCell Line, TumorCell ProliferationMice

Keywords

EpigeneticsDNA methylationCancer researchGene knockdownMesotheliomaMedicineGene expressionBiologyCell culturePathologyGeneGeneticsPrognosistherapeutic targetMalignant Pleural MesotheliomaDnmt1Uhrf1

Sustainable Development Goals

SDG 0: Good health and well-being

UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma

FAIR Checklist

Authors (23)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)